A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening

PHASE3TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 7, 2019

Primary Completion Date

December 5, 2019

Study Completion Date

April 11, 2020

Conditions
Induction of Labor Affected Fetus / Newborn
Interventions
DRUG

Outpatient Dinoprostone 10mg

Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.

DRUG

Inpatient Dinoprostone 10 mg

Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.

Trial Locations (1)

84790

Dixie Regional Medical Center, St. George

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Intermountain Health Care, Inc.

OTHER